# A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

> **NCT05955872** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 21 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis (FSGS)

## Interventions

- **DRUG:** VX-147

## Key facts

- **NCT ID:** NCT05955872
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-19
- **Primary completion:** 2023-09-02
- **Final completion:** 2023-09-02
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955872, "A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05955872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*